THE LIPOSOME COMPANY's ABELCET (ABLC) GAINS APPROVAL FOR ASPERGILLOSIS IN SIX MONTHS -- FIRM's FIRST DRUG IN THE U.S.; LAUNCH EXPECTED IN JANUARY
The Liposome Company's amphotericin B lipid complex Abelcet (formerly called ABLC), was approved Nov. 20 by FDA for treatment of patients with the systemic fungal infection aspergillosis who are refractory to or intolerant of conventional amphotericin B therapy. The NDA was submitted May 24 and was given a priority review by FDA in just under six months.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth